Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2)
1994

Effects of Pravastatin and D-Limonene on Cancer Cell Growth

publication Evidence: moderate

Author Information

Author(s): S. Kawata, T. Nagase, E. Yamasaki, H. Ishiguro, Y. Matsuzawa

Primary Institution: Osaka University Medical School

Hypothesis

The combination of pravastatin and d-limonene will inhibit cancer cell growth more effectively than either agent alone.

Conclusion

The combination of pravastatin and d-limonene significantly suppresses DNA synthesis and the production of a cancer-related protein in Hep G2 cells.

Supporting Evidence

  • Pravastatin alone inhibited cholesterol biosynthesis by 85%.
  • The combination of pravastatin and d-limonene suppressed DNA synthesis to 50% of the control level.
  • Production of m-p21ras was decreased to 35% of the control level by the combination of both inhibitors.
  • D-Limonene did not significantly suppress DNA synthesis at lower concentrations.

Takeaway

Using two drugs together, pravastatin and d-limonene, can help slow down the growth of cancer cells by affecting how proteins are made in those cells.

Methodology

The study involved culturing Hep G2 cells and human fibroblasts with varying concentrations of pravastatin and d-limonene, followed by assays to measure DNA synthesis and protein production.

Limitations

The study primarily focused on in vitro effects, which may not fully represent in vivo conditions.

Participant Demographics

The study used human hepatoma-derived cell line Hep G2 and human skin fibroblasts.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication